Global Information
회사소개 | 문의 | 비교리스트

세계의 신경 자극 기기 시장 분석과 예측 : 삽입형 신경 자극 기기(척수 자극 기기, 청각 뇌간 이식(ABI), 심부 뇌자극 기기, 미주신경 자극(VNS) 기기, 천골신경 자극(SNS) 기기, 설하신경 자극 기기), 비삽입형 신경 자극 기기(2019-2024년)

Global Neurostimulation Devices Market: Focus on Technology Type, Application,17 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2024

리서치사 BIS Research Inc.
발행일 2019년 05월 상품 코드 847126
페이지 정보 영문
가격
US $ 5,000 ₩ 5,942,000 PDF (Single User License/1-3 Users)
US $ 8,000 ₩ 9,507,000 PDF and Excel (Global License)


세계의 신경 자극 기기 시장 분석과 예측 : 삽입형 신경 자극 기기(척수 자극 기기, 청각 뇌간 이식(ABI), 심부 뇌자극 기기, 미주신경 자극(VNS) 기기, 천골신경 자극(SNS) 기기, 설하신경 자극 기기), 비삽입형 신경 자극 기기(2019-2024년) Global Neurostimulation Devices Market: Focus on Technology Type, Application,17 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2024
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 신경 자극 기기 시장은 2024년까지 119억 6,000만 달러에 이를 것으로 예측됩니다.

세계의 신경 자극 기기(Neurostimulation Devices) 시장을 조사했으며, 시장 및 제품 개요, 시장 성장 영향요인 및 시장 기회 분석, 부문·지역/주요 국가별 동향, 시장 규모 추이와 예측, 경쟁 환경, 주요 기업 개요 등의 체계적인 정보를 제공합니다.

주요 요약

제1장 시장 개요

제2장 시장 역학

  • 개요
  • 영향 분석
  • 시장 성장 촉진요인
  • 시장의 과제
  • 성장 기회

제3장 경쟁 구도

  • 주요 전략과 전개
  • 시장 점유율 분석
  • 시장 점유율 분석 : 척수 자극 기기
  • 시장 점유율 분석 : 심부 뇌자극 기기
  • 시장 점유율 분석 : 청각 뇌간 이식(ABI)
  • 성장 점유율 분석

제4장 규제 프레임워크

  • 규제 조직/기관/컨소시엄
  • 특허 상황
  • 제품 파이프라인 테이블 : 신경 자극 기기 시장의 제품 파이프라인

제5장 세계의 신경 자극 기기 시장 : 제품별

  • 개요
  • 삽입형 신경 자극 기기
    • 척수 자극 기기
    • 청각 뇌간 이식(ABI)
    • 심부 뇌자극 기기
    • 미주신경 자극(VNS) 기기
    • 선골신경 자극(SNS) 기기
    • 설하신경 자극 기기
    • 기타
  • 비삽입형 신경 자극 기기

제6장 세계의 신경 자극 기기 시장 : 용도별

  • 개요
  • 통증관리
  • 난청
  • 파킨슨병
  • 간질
  • 요실금, 변실금
  • 우울증
  • 기타

제7장 세계의 신경 자극 기기 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카

제8장 기업 개요

  • 제품 분석
  • 개요
  • Abbott Laboratories
  • Bayer AG
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • Helius Medical Technologies, Inc.
  • Inspire Medical Systems, Inc.
  • Laborie Medical Technologies, Inc.
  • LivaNova PLC
  • Medtronic plc
  • NeuroMetrix, Inc.
  • Nuvectra Corporation
  • SPR Therapeutics, LLC
  • STYMCO Medical, LLC
  • Synapse Biomedical Inc.

제9장 조사 범위와 방법

LSH 19.05.28

List of Tables

  • Table 1: Mortality Due to Opioid-Use Disorders
  • Table 2.1: Impact Analysis of Market Drivers
  • Table 2.2: Impact Analysis of Market Challenges
  • Table 4.1: Regulatory Bodies Related to Neurostimulation Devices (by Country)
  • Table 7.1: North America Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.2: The U.S. Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.3: The Canada Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.4: Europe Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.5: Germany Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.6: The U.K. Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.7: France Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.8: Italy: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.9: Spain: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.10: Russia: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.11: Switzerland: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.12: Asia- Pacific Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.13: Japan: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.14: China: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.15: India: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.16: Australia: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.17: South Korea: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.18: Brazil: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.19: Mexico: Disability-Adjusted Life Years (DALYs), 2014-2017
  • Table 7.20: Argentina: Disability-adjusted Life Years (DALYs), 2014-2017

List of Figures

  • Figure 1: Annual Societal Costs of Medical Conditions, the U.S., 2014
  • Figure 2: Impact of Chronic Pain on Routine Activities
  • Figure 3: Market Drivers and Market Restraints
  • Figure 4: Market Statistics
  • Figure 5: Competitive Scenario
  • Figure 6: Global Neurostimulation Devices Market, 2018-2024
  • Figure 7: Growth Share Matrix of Products, 2017
  • Figure 8: Global Neurostimulation Devices Market (by Application), 2018 and 2024
  • Figure 9: Growth Share Analysis (by Country), 2017
  • Figure 1.1: Evolution of Neurostimulation Technologies
  • Figure 1.2: Segmentation of Neurostimulation Devices Market
  • Figure 1.3: Global Neurostimulation Devices Market, 2018-2024
  • Figure 2.1: Market Dynamics
  • Figure 2.2: U.S. Annual Alzheimer's Death Rate (per 100,000 People) by Year
  • Figure 2.3: Ages of People with Alzheimer's Dementia in the United States, 2018
  • Figure 3.1: Competitive Landscape, January 2015-February 2019
  • Figure 3.2: Share of Key Developments and Strategies, January 2015-February 2019
  • Figure 3.3: Product Launches (by Company), January 2015-February 2019
  • Figure 3.4: Collaborations, Joint Ventures, and Partnerships Share (by Company), January 2015-February 2019
  • Figure 3.5: Mergers and Acquisitions Share (by Company), January 2015-February 2019
  • Figure 3.6: Awards and Recognition (by Company), January 2015-February 2019
  • Figure 3.7: Business Expansion and Others Share (by Company), January 2015- February 2019
  • Figure 3.8: Market Share Analysis (by Company), for Global Neurostimulation Devices Market, 2016 and 2017
  • Figure 3.9: Market Share Analysis (by Company), for Global Spinal Cord Stimulation Devices Market, 2016 and 2017
  • Figure 3.10: Market Share Analysis (by Company), for Global Deep Brain Stimulation Devices Market, 2016 and 2017
  • Figure 3.11: Market Share Analysis (by Company), for Global Auditory Brainstem Implants Market, 2016 and 2017
  • Figure 3.12: Growth Share Matrix for Global Neurostimulation Devices Market (by Product), 2017
  • Figure 4.1: Share of Patents (by Ownership), 2015-2018
  • Figure 5.1: Neurostimulation Devices Market Segmentation (by Product)
  • Figure 5.2: Global Neurostimulation Devices Market (by Product), 2018 and 2024
  • Figure 5.3: Global Implantable Neurostimulation Devices Market, 2018 and 2024
  • Figure 5.4: Global Spinal Cord Stimulation Devices Market, (2018-2024)
  • Figure 5.5: Global Auditory Brainstem Implant Market, (2018-2024)
  • Figure 5.6: Global Deep Brain Stimulation Devices Market, (2018-2024)
  • Figure 5.7: Global Vagus Nerve Stimulation Devices Market, (2018-2024)
  • Figure 5.8: Global Sacral Nerve Stimulation Devices Market, (2018-2024)
  • Figure 5.9: Global Hypoglossal Nerve Stimulation Devices Market, (2018-2024)
  • Figure 5.10: Other Neurostimulation Devices Market, (2018-2024)
  • Figure 5.11: Global Neurostimulation Devices Market (by Non- Implantable Neurostimulation Device Type), 2018-2024
  • Figure 6.1: Segmentation of Neurostimulation Devices Market (by Application)
  • Figure 6.2: Global Neurostimulation Devices Market (by Application), 2018 and 2024
  • Figure 6.3: Global Neurostimulation Devices Market (by Pain Management), 2018-2024
  • Figure 6.4: Global Neurostimulation Devices Market (by Hearing Loss), 2018-2024
  • Figure 6.5: Global Neurostimulation devices Market (by Parkinson's disease), 2018-2024
  • Figure 6.6: Global Neurostimulation Devices Market (by Epilepsy), 2018-2024
  • Figure 6.7: Global Neurostimulation Devices Market (by Urinary and Fecal Incontinence), 2018-2024
  • Figure 6.8: Global Neurostimulation Devices Market (by Depression), 2018-2024
  • Figure 6.9: Global Neurostimulation Devices Market (by Other Applications), 2018-2024
  • Figure 7.1: Global Neurostimulation Devices Market (by Region), 2018 and 2024
  • Figure 7.2: North America: Neurostimulation Devices Market, 2018-2024
  • Figure 7.3: North America: Market Dynamics
  • Figure 7.4: North America: Neurostimulation Devices Market (by Country), 2018 and 2024
  • Figure 7.5: U.S.: Neurostimulation Devices Market, 2018-2024
  • Figure 7.6: Canada: Neurostimulation Devices Market, 2018-2024
  • Figure 7.7: Europe: Neurostimulation Devices Market, 2018-2024
  • Figure 7.8: Europe: Market Dynamics
  • Figure 7.9: Europe: Neurostimulation Devices Market (by Country), 2018 and 2024
  • Figure 7.10: Germany: Neurostimulation Devices Market, 2018-2024
  • Figure 7.11: U.K.: Neurostimulation Devices Market, 2018-2024
  • Figure 7.12: France: Neurostimulation Devices Market, 2018-2024
  • Figure 7.13: Italy: Neurostimulation Devices Market, 2018-2024
  • Figure 7.14: Spain: Neurostimulation Devices Market, 2018-2024
  • Figure 7.15: Russia: Neurostimulation Devices Market, 2018-2024
  • Figure 7.16: Switzerland: Neurostimulation Devices Market, 2018-2024
  • Figure 7.17: Rest-of-Europe: Neurostimulation Devices Market, 2018-2024
  • Figure 7.18: Asia-Pacific: Neurostimulation Devices Market, 2018-2024
  • Figure 7.19: Asia-Pacific: Market Dynamics
  • Figure 7.20: Asia-Pacific: Neurostimulation Devices Market (by Country), 2018 and 2024
  • Figure 7.21: Japan: Neurostimulation Devices Market, 2018-2024
  • Figure 7.22: China: Neurostimulation Devices Market, 2018-2024
  • Figure 7.23: India: Neurostimulation Devices Market, 2018-2024
  • Figure 7.24: Australia: Neurostimulation Devices Market, 2018-2024
  • Figure 7.25: South Korea: Neurostimulation Devices Market, 2018-2024
  • Figure 7.26: Rest-of-Asia-Pacific: Neurostimulation Devices Market, 2018-2024
  • Figure 7.27: Latin America: Neurostimulation Devices Market, 2018-2024
  • Figure 7.28: Latin-America: Market Dynamics
  • Figure 7.29: Latin-America: Neurostimulation Devices Market (by Country), 2018 and 2024
  • Figure 7.30: Brazil: Neurostimulation Devices Market, 2018-2024
  • Figure 7.31: Mexico: Neurostimulation Devices Market, 2018-2024
  • Figure 7.32: Argentina: Neurostimulation Devices Market, 2018-2024
  • Figure 7.33: Rest-of-Latin America: Neurostimulation Devices Market, 2018-2024
  • Figure 7.34: Rest-of-the-World: Neurostimulation Devices Market, 2018-2024
  • Figure 8.1: Market Scenario
  • Figure 8.2: Growth Share Matrix for Global Neurostimulation Devices Market (by Prominent Companies), 2017
  • Figure 8.3: Shares of Key Company Profiles
  • Figure 8.4: Abbott Laboratories: Overall Product Portfolio
  • Figure 8.5: Abbott Laboratories: Overall Financials, 2015-2017
  • Figure 8.6: Abbott Laboratories: Revenue (by Segment), 2015-2017
  • Figure 8.7: Abbott Laboratories: Revenue (by Region), 2015-2017
  • Figure 8.8: Abbott Laboratories: R&D Expenditure, 2015-2017
  • Figure 8.9: Abbott Laboratories: SWOT Analysis
  • Figure 8.10: Bayer AG: Overall Product Portfolio
  • Figure 8.11: Bayer AG: Overall Financials, 2016-2018
  • Figure 8.12: Bayer AG: Revenue (by Segment), 2016-2018
  • Figure 8.13: Bayer AG: Revenue (by Region), 2016-2018
  • Figure 8.14: Bayer AG: R&D Expenditure, 2016-2018
  • Figure 8.15: Bayer AG: SWOT Analysis
  • Figure 8.16: Boston Scientific Corporation: Overall Product Portfolio
  • Figure 8.17: Boston Scientific Corporation: Overall Financials, 2015-2017
  • Figure 8.18: Boston Scientific Corporation: Revenue (by Segment), 2015-2017
  • Figure 8.19: Boston Scientific Corporation: Revenue (by Sub-segment), 2015-2017
  • Figure 8.20: Boston Scientific Corporation: R&D Expenditure, 2015-2017
  • Figure 8.21. Boston Scientific Corporation: SWOT Analysis
  • Figure 8.22: Cochlear Ltd.: Product Portfolio for Neurostimulation Devices Market
  • Figure 8.23: Cochlear Ltd.: Overall Financials, 2016-2018
  • Figure 8.24: Cochlear Ltd.: Revenue (by Segment), 2016-2018
  • Figure 8.25: Cochlear Ltd.: Revenue (by Region), 2016-2018
  • Figure 8.26: Cochlear Ltd.: R&D Expenditure
  • Figure 8.27: Cochlear Ltd.: SWOT Analysis
  • Figure 8.28: Helius Medical Technologies, Inc.: Overall Product Portfolio
  • Figure 8.29: Helius Medical Technologies, Inc.: SWOT Analysis
  • Figure 8.30: Inspire Medical System, Inc.: Overall Product Portfolio
  • Figure 8.31: Inspire Medical System, Inc.: Overall Financials, 2016-2018
  • Figure 8.32: Inspire Medical System, Inc.: Revenue (by Region), 2015-2017
  • Figure 8.33: Inspire Medical System, Inc.: R&D Expenditure, 2015-2017
  • Figure 8.34: Inspire Medical System Inc.: SWOT Analysis
  • Figure 8.35: Laborie Medical Technologies, Inc.: Overall Product Portfolio
  • Figure 8.36: Laborie Medical Technologies, Inc.: SWOT Analysis
  • Figure 8.37: LivaNova PLC: Overall Product Portfolio
  • Figure 8.38: LivaNova PLC: Overall Financials, 2015-2017
  • Figure 8.39: LivaNova PLC (by Segment), 2015-2017
  • Figure 8.40: LivaNova PLC: Revenue (by Region), 2015-2017
  • Figure 8.41: LivaNova PLC: Revenue for neuromodulation segment (by Region), 2015-2017
  • Figure 8.42: LivaNova PLC: R&D Expenditure, 2015-2017
  • Figure 8.43: LivaNova PLC: SWOT Analysis
  • Figure 8.44: Medtronic plc: Overall Product Portfolio
  • Figure 8.45: Medtronic plc: Overall Financials, 2016-2018
  • Figure 8.46: Medtronic plc: Revenue (by Segment), 2016-2018
  • Figure 8.47: Medtronic plc: Revenue (by Region), 2016-2018
  • Figure 8.48: Medtronic plc: R&D Expenditure, 2016-2018
  • Figure 8.49: Medtronic plc: SWOT Analysis
  • Figure 8.50: NeuroMetrix, Inc.: Overall Product Portfolio
  • Figure 8.51: NeuroMetrix, Inc.: Overall Financials, 2015-2017
  • Figure 8.52: NeuroMetrix, Inc.: R&D Expenditure, 2016-2018
  • Figure 8.53: NeuroMetrix, Inc.: SWOT Analysis
  • Figure 8.54: NeuroPace, Inc.: Overall Product Portfolio
  • Figure 8.55: NeuroPace, Inc.: SWOT Analysis
  • Figure 8.56: Nuvectra Corporation: Overall Product Portfolio
  • Figure 8.57: Nuvectra Corporation: Overall Financials, 2016-2018
  • Figure 8.58: Nuvectra Corporation: Revenue (by Segment), 2016-2018
  • Figure 8.59: Nuvectra Corporation: Revenue (by Region), 2016-2018
  • Figure 8.60: Nuvectra Corporation: R&D Expenditure, 2016-2018
  • Figure 8.61: Nuvectra Corporation: SWOT Analysis
  • Figure 8.62: SPR Therapeutics, LLC: Overall Product Portfolio
  • Figure 8.63: SPR Therapeutics, LLC: SWOT Analysis
  • Figure 8.64: STYMCO Medical, LLC: Overall Product Portfolio
  • Figure 8.65: STYMCO Medical, LLC: SWOT Analysis
  • Figure 8.66: Synapse Biomedical Inc.: Overall Product Portfolio
  • Figure 8.67: Synapse Biomedical Inc.: SWOT Analysis
  • Figure 9.1: Global Neurostimulation Devices Market Segmentation
  • Figure 9.2: Global Neurostimulation Devices Market Research Methodology
  • Figure 9.3: Primary Research
  • Figure 9.4: Secondary Research
  • Figure 9.5: Data Triangulation
  • Figure 9.6: Bottom-up Approach (Segment-wise Analysis)
  • Figure 9.7: Top-down Approach (Segment-wise Analysis)
  • Figure 9.8: Assumptions and Limitations
  • Figure 9.9: Considered Factors for Data Prediction and Modeling

"Global Neurostimulation Devices Market to Reach $11.96 Billion by 2024."

The emergence of sedentary lifestyles, growing geriatric population, physical and mental stress have resulted in different healthcare concerns. Neurological disorders are one of the leading medical conditions which is contributing predominantly to the global healthcare market. The rising prevalence of different types of neurological disorders, a recurring requirement of neuromodulation therapies, and geriatric population medication are attributing to the growth of the neurostimulation devices market.

Presently, product categories within the neurostimulation devices market include spinal cord stimulation devices, auditory brainstem implants, deep brain stimulation devices, sacral nerve stimulation devices, vagus nerve stimulation devices, and non-implantable devices. Till date, the healthcare industry has witnessed a number of successful products for neuromodulation in various applications such as chronic pain, epilepsy, depression, Parkinson's, urinary and fecal incontinence. Further, several players are now focusing on the development of advanced technology based neuromodulation devices which is anticipated to enhance the growth of the entire market.

The purpose of the study is to gain a holistic view of the global neurostimulation devices market in terms of various factors influencing the market, including regulatory reforms and technological advancements. The market has been segmented into 'products,' 'applications,' and 'regions.' The scope of this report is centered upon conducting a detailed study of the products allied with the neurostimulation devices market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape (including pipeline analysis), market share of leading manufacturers, the growth potential of each product, application, and region, as well as other vital information with respect to the market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global neurostimulation devices market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global neurostimulation devices market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple regions, growth of the market in each region for different applications, and the key strategies and developments by the prominent neurostimulation devices manufacturers.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global neurostimulation devices market?
  • What are the underlying structures resulting in the emerging trends within the industry?
  • What was the market value of the leading segments and sub-segments of the global neurostimulation devices market in 2018?
  • How is each segment of the global neurostimulation market expected to grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2024?
  • What are the influencing factors that may affect the market share of the key players?
  • How is the industry expected to evolve during the forecast period, 2019- 2024?
  • What are the key developmental strategies which are being implemented by the key players in order to sustain in the competitive market?
  • What are the key product types in neurostimulation devices market? What are the major benefits of each product type?
  • How has the market been segmented on the basis of application? Which application is dominating the global neurostimulation devices market and its reason?
  • Who are the key manufacturers in neurostimulation devices market and what are their contributions?
  • What is the status of each major human microbiome modulators manufacturer with respect to their pipeline?
  • What is the scope of each neuromodulation product in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • What are the key regulatory implications in developed and developing regions for neurostimulation devices?
  • What is the growth potential of neurostimulation devices in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • Which neurostimulation device has the most promising growth and in which application type?

The key manufacturers who have been contributing significantly to the neurostimulation devices market include: Abbott Laboratories, Beijing Pins Medical Co. Ltd., Boston Scientific Corporation, Medtronic plc, Nexeon MedSystems Inc. Major players in the non-implantable neurostimulation products are Brainsway Ltd., NeuroMetrix, Inc., and Electocore Inc., among others.

Executive Summary

The emergence of factors such as changing dietary habits, irregular sleep patterns, sedentary lifestyles, and stringent work patterns involving prolonged work duration, poor body postures, repetitive trauma, and high levels of anxiety and stress are the leading causes of neurological disorders and chronic pain. Further, the high prevalence of road accidents resulting in devastating traumatic injury has significantly increased the cases of spinal cord injuries resulting in dysfunctioning of the nervous system. According to the Global Health Data Exchange, in 2017 the combined global incidence of neurological disorders and chronic pain was 3.97 billion, which includes several medical conditions such as Alzheimer's disease and other dementias, low back pain, stroke, traumatic brain injury, migraine, epilepsy, multiple sclerosis, spinal cord injury, and Parkinson's disease.

Another largely undermined factor of rising neuromodulation therapy is chronic pain. According to the World Health Organization (WHO), four of top 10 leading causes of disability were chronic pain conditions that include migraine, lower back pain, neck pain, and musculoskeletal disorders, in 2013. Despite the high economic burden, chronic pain also has several detrimental effects on the quality of lives of the patient population and their respective families. Accompanied by the high risk of significant disability, chronic pain also leads to psychological disorders such as depression and anxiety. More than 30% of chronic pain-affected population reported difficulty in handling mundane tasks such as cleaning, bathing, driving, sleeping, participating in fitness activities, and participating in social activities.

As of 2018, the neurostimulation devices market can be seen to have exposure in various countries. Additionally, with the rapid advancements taking place and an exponential progression in the number of companies entering the space, access to consumers is bound to become easier. The global neurostimulation devices market has been witnessing annual growth rate of approximately 13.14% in past three years (2015-2018), and the market is expected to continue to grow with the CAGR of 9.23% during the forecast period, 2019-2024. Growing at a CAGR of 9.32% during the forecast period of 2019-2024, the spinal cord stimulation devices segment is anticipated to generate a value of $4.7 billion in 2024. However, the global market for auditory implants is anticipated to grow at the fastest CAGR of 12.94% during the forecast period 2019-2024.

The purpose of the study is to gain a holistic view of the global neurostimulation devices market in terms of various factors such as recent trends and product advancements, influencing the market. The scope of this report is centered upon conducting a detailed study of the products allied with the neurostimulation devices market, which includes various products such as spinal cord stimulation devices, auditory brainstem Implant, deep brain stimulation, vagus nerve stimulation devices, and sacral nerve stimulation devices. The neurostimulation devices market is segmented into three different parts, namely products, applications, and region. The global market value was estimated on the basis of these three different approaches which were validated against one another. These segments are further segmented into several sub-segments to ease the market estimation and to gain a holistic view of the market.

Based on region, the global neurostimulation devices market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor in the global neurostimulation devices market and was responsible for a 64.19% share of the global market values in 2018. However, Asia-Pacific is expected to grow the fastest among all other regions with a CAGR of 13.51% during the forecast period 2019-2024.

The key neurostimulation devices manufacturers which have been contributing significantly to the neurostimulation devices market include Cochlear Ltd., Abbott Laboratories, and Neuronetics Inc., Nexstim Plc, ElectroCore, Inc., Mainstay Medical International plc, Nexeon MedSystems Inc., Axonics Modulation Technologies, Inc., Allergan plc, and Helius Medical Technology, among others.

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. Evolution of the Neurostimulation therapy
  • 1.2. Enabling Technologies Evolving Neurostimulation Therapies
  • 1.3. Benefits of Neurostimulation technology
  • 1.4. Global Market Scenario
  • 1.5. Assumptions and Limitations

2. Market Dynamics

  • 2.1. Overview
  • 2.2. Impact Analysis
  • 2.3. Market Drivers
    • 2.3.1. Growing Incidence of Neurological Disorders
    • 2.3.2. Increased Side-Effects of Pain Management Medications in Geriatric Population
    • 2.3.3. Limited Success Rate of Drugs Targeting Specific Disease
    • 2.3.4. Advent of Sedentary Lifestyles Resulting Massive Burden of Chronic Pain
    • 2.3.5. Growing Concerns Pertaining to Pelvic Health of Geriatric Population
  • 2.4. Market Challenge
    • 2.4.1. Financial Burden of Product Recalls
    • 2.4.2. Lack of Long Term Clinical Studies
    • 2.4.3. Lack of Pain Specialist
    • 2.4.4. Increased Regulatory Scrutiny
  • 2.5. Market Opportunities
    • 2.5.1. Evolution of Biomarker-Based Therapeutics Enabling Early Diagnostics of Neurological Disorders
    • 2.5.2. Development of Closed Loop Neuromodulation

3. Competitive Landscape

  • 3.1. Key Strategies and Developments
    • 3.1.1. Product Launches
    • 3.1.2. Collaborations, Joint Ventures, and Partnerships
    • 3.1.3. Mergers and Acquisitions
    • 3.1.4. Awards and Recognitions
    • 3.1.5. Business Expansion and Others
  • 3.2. Market Share Analysis (2016 and 2017)
  • 3.3. Market Share Analysis for Global Spinal Cord Stimulation Devices Market, 2016 and 2017
  • 3.4. Market Share Analysis for Global Deep Brain Stimulation Devices Market, 2016 and 2017
  • 3.5. Market Share Analysis for Global Auditory Brainstem Implants Market, 2016 and 2017
  • 3.6. Growth Share Analysis

4. Regulatory Framework

  • 4.1. Regulatory Organizations/ Associations/ Consortiums
  • 4.2. Patent Landscape
  • 4.3. Product Pipeline Table: Product Pipeline for Neurostimulation Devices Market

5. Global Neurostimulation Devices Market (by Product)

  • 5.1. Overview
  • 5.2. Implantable Neurostimulation Devices
    • 5.2.1. Spinal Cord Stimulation Devices
    • 5.2.2. Auditory Brainstem Implant
    • 5.2.3. Deep Brain Stimulation
    • 5.2.4. Vagus Nerve Stimulation(VNS) Devices
    • 5.2.5. Sacral Nerve Stimulation (SNS) Devices
    • 5.2.6. Hypoglossal Nerve Stimulation
    • 5.2.7. Others
  • 5.3. Non-Implantable Neurostimulation Devices

6. Global Neurostimulation Devices Market (by Application)

  • 6.1. Overview
  • 6.2. Pain Management
  • 6.3. Hearing Loss
  • 6.4. Parkinson's Disease
  • 6.5. Epilepsy
  • 6.6. Urinary and Fecal Incontinence
  • 6.7. Depression
  • 6.8. Others

7. Global Neurostimulation Devices Market (by Region)

  • 7.1. Global Overview
  • 7.2. North America
    • 7.2.1. The U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. The U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Switzerland
    • 7.3.8. Rest-of-Europe
  • 7.4. Asia-Pacific
    • 7.4.1. Japan
    • 7.4.2. China
    • 7.4.3. India
    • 7.4.4. Australia
    • 7.4.5. South Korea
    • 7.4.6. Rest-of-Asia-Pacific
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Argentina
    • 7.5.4. Rest-of-Latin America
  • 7.6. Rest-of-the-World

8. Company Profiles

  • 8.1. Product Analysis
    • 8.1.1. Growth Share Analysis (by Prominent Companies)
  • 8.2. Overview
  • 8.3. Abbott Laboratories
    • 8.3.1. Company Overview
    • 8.3.2. Role of Abbott Laboratories in the Neurostimulation Device Market
    • 8.3.3. Financials
      • 8.3.3.1. Key Insights about Financial Health of the Company
    • 8.3.4. SWOT Analysis
  • 8.4. Bayer AG
    • 8.4.1. Company Overview
    • 8.4.2. Role of Bayer AG in the Neurostimulation Devices Market
      • 8.4.2.1. Key Insights about Financial Health of the Company
    • 8.4.3. SWOT Analysis
  • 8.5. Boston Scientific Corporation
    • 8.5.1. Company Overview
    • 8.5.2. Role of Boston Scientific Corporation in the Neurostimulation Devices Market
    • 8.5.3. Financials
      • 8.5.3.1. Key Insights about Financial Health of the Company
    • 8.5.4. SWOT Analysis
  • 8.6. Cochlear Ltd.
    • 8.6.1. Company Overview
    • 8.6.2. Role of Cochlear Ltd. In the Neurostimulation Devices Market
      • 8.6.2.1. Key Insights about Financial Health of the Company
    • 8.6.3. SWOT Analysis
  • 8.7. Helius Medical Technologies, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Helius Medical Technologies, Inc. in the Neurostimulation Devices Market
    • 8.7.3. SWOT Analysis
  • 8.8. Inspire Medical Systems, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Role of Inspire Medical System, Inc. in the Neurostimulation Devices Market
    • 8.8.3. Financials
      • 8.8.3.1. Key Insights about Financial Health of the Company
    • 8.8.4. SWOT Analysis
  • 8.9. Laborie Medical Technologies, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Role of Laborie Medical Technologies, Inc. in the Neurostimulation Devices Market
    • 8.9.3. SWOT Analysis
  • 8.10 LivaNova PLC
    • 8.10.1. Company Overview
    • 8.10.2. Role of LivaNova PLC in the Neurostimulation Devices Market
    • 8.10.3. Financials
      • 8.10.3.1. Key Insights about Financial Health of the Company
    • 8.10.4. SWOT Analysis
  • 8.11. Medtronic plc
    • 8.11.1. Company Overview
    • 8.11.2. Role of Medtronic plc in the Neurostimulation Devices Market
    • 8.11.3. Financials
      • 8.11.3.1. Key Insights about Financial Health of the Company
    • 8.11.4. SWOT Analysis
  • 8.12. NeuroMetrix, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Role of NeuroMetrix, Inc. in the Neurostimulation Devices Market
    • 8.12.3. Financials
      • 8.12.3.1. Key Insights about Financial Health of the Company
    • 8.12.4. SWOT Analysis
  • 8.13. NeuroPace, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Role of NeuroPace, Inc. in the Neurostimulation Devices Market
    • 8.13.3. SWOT Analysis
  • 8.14. Nuvectra Corporation
    • 8.14.1 Company Overview
    • 8.14.2. Role of Nuvectra Corporation in the Neurostimulation Device Market
    • 8.14.3. Financials
      • 8.14.3.1. Key Insights about Financial Health of the Company
    • 8.14.4. SWOT Analysis
  • 8.15. SPR Therapeutics, LLC
    • 8.15.1. Company Overview
    • 8.15.2. Role of SPR Therapeutics, LLC in the Neurostimulation Devices Market
    • 8.15.3. SWOT Analysis
  • 8.16. STYMCO Medical, LLC
    • 8.16.1. Company Overview
    • 8.16.2. Role of STYMCO Medical, LLC in the Neurostimulation Devices Market
    • 8.16.3. SWOT Analysis
  • 8.17. Synapse Biomedical Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Role of Synapse Biomedical Inc. in the Neurostimulation Devices Market
    • 8.17.3. SWOT Analysis

9. Research Scope and Methodology

  • 9.1. Product Definition
  • 9.2. Scope of the Research Study
Back to Top
전화 문의
F A Q